High rates of substance use disorders (SUD) among psychiatric patients are well documented. This study explores the usefulness of the Alcohol Use Disorders Identification Test (AUDIT) and the Drug Use Disorders Identification Test (DUDIT) in identifying SUD in emergency psychiatric patients. Of 287 patients admitted consecutively, 256 participants (89%) were included, and 61-64% completed the questionnaires and the Mini-International Neuropsychiatric Interview (MINI), used as the reference standard. Both AUDIT and DUDIT were valid (area under the curve above 0.92) and reliable (Cronbach's alpha above 0.89) in psychotic and nonpsychotic men and women. The suitable cutoff scores for AUDIT were higher among the psychotic than nonpsychotic patients, with 12 versus 10 in men and 8 versus 5 in women. The suitable cutoff scores for DUDIT were 1 in both psychotic and nonpsychotic women, and 5 versus 1 in psychotic and nonpsychotic men, respectively. This study shows that AUDIT and DUDIT may provide precise information about emergency psychiatric patients' problematic alcohol and drug use.

1.
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-2518.
2.
Hansen SS, Munk-Jorgensen P, Guldbaek B, Solgard T, Lauszus KS, Albrechtsen N, Borg L, Egander A, Faurholdt K, Gilberg A, Gosden NP, Lorenzen J, Richelsen B, Weischer K, Bertelsen A: Psychoactive substance use diagnoses among psychiatric in-patients. Acta Psychiatr Scand 2000;102:432-438.
3.
Lehman AF, Myers CP, Corty E, Thompson JW: Prevalence and patterns of ‘dual diagnosis' among psychiatric inpatients. Compr Psychiatry 1994;35:106-112.
4.
McCloud A, Barnaby B, Omu N, Drummond C, Aboud A: Relationship between alcohol use disorders and suicidality in a psychiatric population: in-patient prevalence study. Br J Psychiatry 2004;184:439-445.
5.
Drake RE, Osher FC, Wallach MA: Alcohol use and abuse in schizophrenia. A prospective community study. J Nerv Ment Dis 1989;177:408-414.
6.
Soyka M: Substance misuse, psychiatric disorder and violent and disturbed behaviour. Br J Psychiatry 2000;176:345-350.
7.
Soyka M, Albus M, Immler B, Kathmann N, Hippius H: Psychopathology in dual-diagnosis and nonaddicted schizophrenics: are there differences? Eur J Health Econ 2002;3(suppl 2):S114-S120.
8.
Tardiff K, Marzuk PM, Leon AC, Portera L, Weiner C: Violence by patients admitted to a private psychiatric hospital. Am J Psychiatry 1997;154:88-93.
9.
Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O'Brien R, Schofield N, McGovern J: Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 2001;158:1706-1713.
10.
Drake RE, McHugo GJ, Clark RE, Teague GB, Xie H, Miles K, Ackerson TH: Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial. Am J Orthopsychiatry 1998;68:201-215.
11.
Hien DA, Cohen LR, Miele GM, Litt LC, Capstick C: Promising treatments for women with comorbid PTSD and substance use disorders. Am J Psychiatry 2004;161:1426-1432.
12.
Milby JB, Schumacher JE, McNamara C, Wallace D, Usdan S, McGill T, Michael M: Initiating abstinence in cocaine abusing dually diagnosed homeless persons. Drug Alcohol Depend 2000;60:55-67.
13.
Petrakis IL, O'Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH: Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 2004;172:291-297.
14.
Schmitz JMP, Averill PP, Sayre SM, McCleary PL, Moeller FGM, Swann AM: Cognitive-behavioral treatment of bipolar disorder and substance abuse: a preliminary randomized study. Addict Disord Their Treat 2002;1:17-24.
15.
Tiet QQ, Mausbach B: Treatments for patients with dual diagnosis: a review. Alcohol Clin Exp Res 2007;31:513-536.
16.
Tiet QQ, Ilgen MA, Byrnes HF, Harris AH, Finney JW: Treatment setting and baseline substance use severity interact to predict patients' outcomes. Addiction 2007;102:432-440.
17.
Spitzer RL, Williams JB, Gibbon M, First MB: The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry 1992;49:624-629.
18.
Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J: Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry 1996;153:1195-1201.
19.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33.
20.
Appleby L, Dyson V, Luchins DJ, Cohen LS: The impact of substance use screening on a public psychiatric inpatient population. Psychiatr Serv 1997;48:1311-1316.
21.
McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M: The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992;9:199-213.
22.
Selzer ML: The Michigan Alcoholism Screening Test: the quest for a new diagnostic instrument. Am J Psychiatry 1971;127:1653-1658.
23.
Ewing JA: Detecting alcoholism. The CAGE questionnaire. JAMA 1984;252:1905-1907.
24.
Skinner HA: The drug abuse screening test. Addict Behav 1982;7:363-371.
25.
Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M: Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption - II. Addiction 1993;88:791-804.
26.
Allen JP, Litten RZ, Fertig JB, Babor T: A review of research on the Alcohol Use Disorders Identification Test (AUDIT). Alcohol Clin Exp Res 1997;21:613-619.
27.
Davis TM, Bush KR, Kivlahan DR, Dobie DJ, Bradley KA: Screening for substance abuse and psychiatric disorders among women patients in a VA Health Care System. Psychiatr Serv 2003;54:214-218.
28.
Fireman M, Indest DW, Blackwell A, Whitehead AJ, Hauser P: Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin Infect Dis 2005;40(suppl 5):S286-S291.
29.
Lieberman DZ: Clinical characteristics of individuals using an online alcohol evaluation program. Am J Addict 2005;14:155-165.
30.
Mendoza-Sassi RA, Beria JU: Prevalence of alcohol use disorders and associated factors: a population-based study using AUDIT in southern Brazil. Addiction 2003;98:799-804.
31.
Reinert DF, Allen JP: The alcohol use disorders identification test: an update of research findings. Alcohol Clin Exp Res 2007;31:185-199.
32.
Berman AH, Bergman H, Palmstierna T, Schlyter F: Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. Eur Addict Res 2005;11:22-31.
33.
Durbeej N, Berman AH, Gumpert CH, Palmstierna T, Kristiansson M, Alm C: Validation of the Alcohol Use Disorders Identification Test and the Drug Use Disorders Identification Test in a Swedish sample of suspected offenders with signs of mental health problems: results from the Mental Disorder, Substance Abuse and Crime Study. J Subst Abuse Treat 2010;39:364-377.
34.
Sinadinovic K, Wennberg P, Berman AH: Population screening of risky alcohol and drug use via Internet and Interactive Voice Response (IVR): a feasibility and psychometric study in a random sample. Drug Alcohol Depend 2011;114:55-60.
35.
Voluse AC, Gioia CJ, Sobell LC, Dum M, Sobell MB, Simco ER: Psychometric properties of the Drug Use Disorders Identification Test (DUDIT) with substance abusers in outpatient and residential treatment. Addict Behav 2012;37:36-41.
36.
Dawe S, Seinen A, Kavanagh D: An examination of the utility of the AUDIT in people with schizophrenia. J Stud Alcohol 2000;61:744-750.
37.
Maisto SA, Carey MP, Carey KB, Gordon CM, Gleason JR: Use of the AUDIT and the DAST-10 to identify alcohol and drug use disorders among adults with a severe and persistent mental illness. Psychol Assess 2000;12:186-192.
38.
Cassidy CM, Schmitz N, Malla A: Validation of the alcohol use disorders identification test and the drug abuse screening test in first episode psychosis. Can J Psychiatry 2008;53:26-33.
39.
Nesvåg R, Lange EH, Faerden A, Barrett EA, Emilsson B, Ringen PA, Andreassen OA, Melle I, Agartz I: The use of screening instruments for detecting alcohol and other drug use disorders in first-episode psychosis. Psychiatry Res 2010;177:228-234.
40.
Cruce G, Nordstrom LG, Ojehagen A: Risky use and misuse of alcohol, drugs and cigarettes detected by screening questionnaires in a clinical psychosis unit. Nord J Psychiatry 2007;61:92-99.
41.
Mordal J, Gundersen O, Bramness JG: Norwegian version of the Mini-International Neuropsychiatric Interview: feasibility, acceptability and test-retest reliability in an acute psychiatric ward. Eur Psychiatry 2010;25:172-177.
42.
Mordal J, Holm B, Gossop M, Romoren M, Morland J, Bramness JG: Psychoactive substance use among patients admitted to an acute psychiatric ward: laboratory findings and associations with clinical characteristics. Nord J Psychiatry 2011;65:208-215.
43.
Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH: The Mini- International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 1997;12:224-231.
44.
Sheehan DV, Lecrubier Y, Sheehan KH, Janavs J, Weiller E, Keskiner A: The validity of the Mini-International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 1997;12:232-241.
45.
Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
46.
Nunnally JC: Psychometric Theory, ed 2. New York, McGraw-Hill, 1978.
47.
Sjöstedt G, Grann M: Risk assessment: what is being predicted by actuarial ‘prediction instruments'? Int J Forensic Mental Health 2002;1:179-183.
48.
Bastiaens L, Riccardi K, Sakhrani D: The RAFFT as a screening tool for adult substance use disorders. Am J Drug Alcohol Abuse 2002;28:681-691.
49.
Riggs SR, Alario A: RAFFT Questions. Project ADEPT Manual. Providence, Brown University, 1987.
50.
Helseth V, Lykke-Enger T, Johnsen J, Waal H: Substance use disorders among psychotic patients admitted to inpatient psychiatric care. Nord J Psychiatry 2009;63:72-77.
51.
Wolford GL, Rosenberg SD, Drake RE, Mueser KT, Oxman TE, Hoffman D, Vidaver RM, Luckoor R, Carrieri KL: Evaluation of methods for detecting substance use disorder in persons with severe mental illness. Psychol Addict Behav 1999;13:313-326.
52.
Ananth J, Vandewater S, Kamal M, Brodsky A, Gamal R, Miller M: Missed diagnosis of substance abuse in psychiatric patients. Hosp Community Psychiatry 1989;40:297-299.
53.
Tiet QQ, Finney JW, Moos RH: Screening psychiatric patients for illicit drug use disorders and problems. Clin Psychol Rev 2008;28:578-591.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.